The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series

REFERENCES

• Abraham, H. D., and A. M. Aldridge. 1993. Adverse consequences of lysergic acid diethylamide. Addiction 88 (10):1327–34. doi:10.1111/j.1360-0443.1993.tb02018.x.
   PubMed Web of Science ®Google Scholar
• Addy, P. H. 2012. Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology 220 (1):195–204. doi:10.1007/s00213-011-2470-6.
   PubMed Web of Science ®Google Scholar
• Albertson, D. N., and L. E. Grubbs. 2009. Subjective effects of Salvia divinorum: LSD- or marijuana-like? Journal of Psychoactive Drugs 41 (3):213–17. doi:10.1080/02791072.2009.10400531.
   PubMed Web of Science ®Google Scholar
• Andréasson, S., P. Allebeck, and U. Rydberg. 1989. Schizophrenia in users and nonusers of cannabis. Acta Psychiatrica Scandinavica 79 (5):505–10. doi:10.1111/j.1600-0447.1989.tb10296.x.
   PubMed Web of Science ®Google Scholar
• Arseneault, L., M. Cannon, J. Witton, and R. M. Murray. 2004. Causal association between cannabis and psychosis: Examination of the evidence. The British Journal of Psychiatry 184 (2):110–17. doi:10.1192/bjp.184.2.110.
   PubMed Web of Science ®Google Scholar
• Cantor-Graae, E., L. G. Nordström, and T. F. McNeil. 2001. Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophrenia Research 48 (1):69–82. doi:10.1016/S0920-9964(00)00114-6.
   PubMed Web of Science ®Google Scholar
• Carlezon, W. A., C. Béguin, J. A. DiNieri, M. H. Baumann, M. R. Richards, M. S. Todtenkopf, R. B. Rothman, Z. Ma, D. Y. Lee, and B. M. Cohen. 2006. Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. Journal of Pharmacology and Experimental Therapeutics 316 (1):440–47. doi:10.1124/jpet.105.092304.
   PubMed Web of Science ®Google Scholar
• Dalgarno, P. 2007. Subjective effects of Salvia divinorum. Journal of Psychoactive Drugs 39 (2):143–49. doi:10.1080/02791072.2007.10399872.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2011. http://www.emcdda.europa.eu/publications/drug-profiles/salvia ( accessed September 15, 2011).
   Google Scholar
• Griffin, O. H., B. Lee Miller, and D. N. Khey. 2008. Legally high? Legal considerations of Salvia divinorum. Journal of Psychoactive Drugs 40 (2):183–91. doi:10.1080/02791072.2008.10400629.
   PubMed Web of Science ®Google Scholar
• Hanes, K. R. 2001. Antidepressant effects of the herb Salvia divinorum: A case report. Journal of Clinical Psychopharmacology 21 (6):634–35. doi:10.1097/00004714-200112000-00025.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., K. A. MacLean, C. J. Reissig, T. E. Prisinzano, and R. R. Griffiths. 2011. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence 115 (1–2):150–55. doi:10.1016/j.drugalcdep.2010.11.005.
   PubMed Web of Science ®Google Scholar
• Kavanagh, D. J., G. Waghorn, L. Jenner, D. C. Chant, V. Carr, M. Evans, H. Hemnan, A. Jablensky, and J. J. McGrath. 2004. Demographic and clinical correlates of comorbid substance use disorders in psychosis: Multivariate analyses from an epidemiological sample. Schizophrenia Research 66 (2–3):115–24. doi:10.1016/S0920-9964(03)00130-0.
   PubMed Web of Science ®Google Scholar
• Kelly, B. C. 2011. Legally tripping: A qualitative profile of Salvia divinorum use among young adults. Journal of Psychoactive Drugs 43 (1):46–54. doi:10.1080/02791072.2011.566500.
   PubMed Web of Science ®Google Scholar
• Kessler, R. C., K. A. McGonagle, S. Zhao, C. B. Nelson, M. Hughes, S. Eshleman, H. U. Wittchen, and K. S. Kendler. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry 51 (1):8–9. doi:10.1001/archpsyc.1994.03950010008002.
   PubMed Web of Science ®Google Scholar
• Lambert, M., P. Conus, D. I. Lubman, D. Wade, H. Yuen, S. Moritz, D. Naber, P. D. McGorry, and B. G. Schimmelmann. 2005. The impact of substance use disorders on clinical outcome in 643 patients with first‐episode psychosis. Acta Psychiatrica Scandinavica 112 (2):141–48. doi:10.1111/j.1600-0447.2005.00554.x.
   PubMed Web of Science ®Google Scholar
• MacLean, K. A., M. W. Johnson, C. J. Reissig, T. E. Prisinzano, and R. R. Griffiths. 2013. Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects. Psychopharmacology 226 (2):381–92. doi:10.1007/s00213-012-2912-9.
   PubMed Web of Science ®Google Scholar
• McDonough, P. C., J. M. Holler, S. P. Vorce, T. Z. Bosy, J. Magluilo, and M. R. Past. 2008. The detection and quantitative analysis of the psychoactive component of Salvia divinorum, salvinorin A, in human biological fluids using liquid chromatography-mass spectrometry. Journal of Analytical Toxicology 32 (6):417–21. doi:10.1093/jat/32.6.417.
   PubMed Web of Science ®Google Scholar
• Niemi-Pynttäri, J. A., R. Sund, H. Putkonen, H. Vorma, K. Wahlbeck, and S. P. Pirkola. 2013. Substance-induced psychoses converting into schizophrenia: A register-based study of 18,478 Finnish inpatient cases. The Journal of Clinical Psychiatry 74 (1):e94–9. doi:10.4088/JCP.12m07822.
   PubMed Web of Science ®Google Scholar
• Paulzen, M., and G. Gründer. 2008. Toxic psychosis after intake of the hallucinogen Salvinorin A. The Journal of Clinical Psychiatry 69 (9):1501–02. doi:10.4088/JCP.v69n0919c.
   PubMed Web of Science ®Google Scholar
• Pfeiffer, A., V. Brantl, A. Herz, and H. M. Emrich. 1986. Psychotomimesis mediated by kappa opiate receptors. Science 233 (4765):774–76. doi:10.1126/science.3016896.
   PubMed Web of Science ®Google Scholar
• Prisinzano, T. E. 2005. Psychopharmacology of the hallucinogenic sage: Salvia divinorum. Life Sciences 78 (5):527–31. doi:10.1016/j.lfs.2005.09.008.
   PubMed Web of Science ®Google Scholar
• Przekop, P., and T. Lee. 2009. Persistent psychosis associated with Salvia divinorum use. American Journal of Psychiatry 166 (7):832–832. doi:10.1176/appi.ajp.2009.08121759.
   PubMed Web of Science ®Google Scholar
• Ranganathan, M., A. Schnakenberg, P. D. Skosnik, B. M. Cohen, B. Pittman, R. A. Sewell, and D. C. D’Souza. 2012. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist salvinorin A in humans. Biological Psychiatry 72 (10):871–79. doi:10.1016/j.biopsych.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Regier, D. A., M. E. Farmer, D. S. Rae, B. Z. Locke, S. J. Keith, L. L. Judd, and F. K. Goodwin. 1990. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA 264 (19):2511–18. doi:10.1001/jama.1990.03450190043026.
   PubMed Web of Science ®Google Scholar
• Roth, B. L., K. Baner, R. Westkaemper, D. Siebert, K. C. Rice, S. Steinberg, P. Ernsberger, and R. B. Rothman. 2002. Salvinorin A: A potent naturally occurring nonnitrogenous   opioid selective agonist. Proceedings of the National Academy of Sciences 99 (18):11934–39. doi:10.1073/pnas.182234399.
   PubMed Web of Science ®Google Scholar
• Seeman, P., H.-C. Guan, and H. Hirbec. 2009. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 63:698–704. doi:10.1002/syn.20647.
   PubMed Web of Science ®Google Scholar
• Shippenberg, T. S. 2009. The dynorphin/kappa opioid receptor system: A new target for the treatment of addiction and affective disorders? Synapse 13:357–69. doi:10.1038/npp.2008.165.
   Web of Science ®Google Scholar
• Shippenberg, T. S., A. Zapata, and V. I. Chefer. 2007. Dynorphin and the pathophysiology of drug addiction. Pharmacology & Therapeutics 116:306–21. doi:10.1016/j.pharmthera.2007.06.011.
   PubMed Web of Science ®Google Scholar
• Simpson, D. S., K. M. Lovell, A. Lozama, N. Han, V. W. Day, C. M. Dersch, R. B. Rothman, and T. E. Prisinzano. 2009. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Role of the furan in affinity for opioid receptors. Organic & Biomolecular Chemistry 7 (18):3748–56. doi:10.1039/b905148a.
   PubMed Web of Science ®Google Scholar
• Singh, S. 2007. Adolescent salvia substance abuse. Addiction 102 (5):823–24. doi:10.1111/j.1360-0443.2007.01810.x.
   PubMed Web of Science ®Google Scholar
• Thirthalli, J., and V. Benegal. 2006. Psychosis among substance users. Current Opinion in Psychiatry 19 (3):239–45. doi:10.1097/01.yco.0000218593.08313.fd.
   PubMed Web of Science ®Google Scholar
• UNODC (United Nations Office on Drugs and Crime) World Drug Report. 2012. Recent statistics and trend analysis of illicit drug markets. United Nations publishing.
   Google Scholar
• US Department of Health and Human Services. 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of national findings. Substance Abuse and Mental Health Services Administration. http://www.samhsa.gov/data/NSDUH/2k10NSDUH/2k10Results.pdf. (accessed June 1, 2014)
   Google Scholar
• US National Institute on Drug Abuse (NIDA). 2013. http://www.drugabuse.gov/drugs-abuse/salvia. (accessed June 1, 2014)
   Google Scholar
• Valdés, L. J. 1994. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. Journal of Psychoactive Drugs 26 (3):277–83. doi:10.1080/02791072.1994.10472441.
   PubMed Web of Science ®Google Scholar
• Valdés, L. J., J. Díaz, and A. G. Paul. 1983. Ethnopharmacology of ska maria pastora (Salvia divinorum, Epling and Játiva-M.). Journal of Ethnopharmacology 7 (3):287–312. doi:10.1016/0378-8741(83)90004-1.
   PubMed Web of Science ®Google Scholar
• Verdoux, H., C. Gindre, F. Sorbara, M. Tournier, and J. D. Swendsen. 2003. Effects of cannabis and psychosis vulnerability in daily life: An experience sampling test study. Psychological Medicine 33 (01):23–32. doi:10.1017/S0033291702006384.
   PubMed Web of Science ®Google Scholar
• Willard, B., and M. Anne. 2011. Forensic analysis of Salvia divinorum and related salvia species using chemometric procedures. Masters Abstracts International 50 (1).
   Google Scholar
• Wu, L. T., G. E. Woody, C. Yang, J. H. Li, and D. G. Blazer. 2011. Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2:53–68. doi:10.2147/SAR.S17192.
   Google Scholar